FOLD Amicus Therapeutics Inc.

13.96
+0.29  (2%)
Previous Close 13.67
Open 13.81
Price To book 8.62
Market Cap 2297342323
Shares 164,566,069
Volume 3,702,229
Short Ratio 12.26
Av. Daily Volume 4,080,946

SEC filingsSee all SEC filings

  1. 8-K - Current report 171091093
  2. 8-K - Current report 171082197
  3. 8-K - Current report 171071668
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 171010626
  5. 8-K - Current report 171009982

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

NDA filing due 4Q 2017. Noted July 11, 2017 that FDA has agreed that further trials will no longer be required, contrary to prior request for an additional Phase 3 trial.
Migalastat
Fabry Disease
"Phase 3 top-line data released September 13, 2017 - endpoints not met. "
SD-101
Epidermolysis Bullosa (EB)
Phase 1/2 additional data released February 15, 2017. Further data released May 15, 2017. Full data due late 3Q 2017.
ATB200
Pompe Disease

Latest News

  1. U.S. FDA Grants Fast Track Designation for Amicus Therapeutics’ Migalastat for Treatment of Fabry Disease
  2. [$$] Clinical Development News, Sept. 11-15
  3. Corporate News Blog - Amicus Therapeutics Reports Phase-3 Results for Sd-101 in Epidermolysis Bullosa did not Meet Primary Endpoints
  4. Amicus Therapeutics Announces Approval for Galafold™ (Migalastat) for Treatment of Fabry Disease in Canada
  5. Amicus abandons wound treatment, focus shifts to future trial data
  6. A father's fight to find a cure for his children's rare disease
  7. Amicus Therapeutics Announces Top-Line Phase 3 Results for SD-101 in Epidermolysis Bullosa
  8. Options Traders Expect Huge Moves in Amicus Therapeutics (FOLD) Stock
  9. Is Amicus Therapeutics Stock Still a Strong Buy?
  10. Time to Bring Amicus Therapeutics Into the 'FOLD'
  11. Amicus Therapeutics to Highlight Fabry Disease Program at the 13th International Congress of Inborn Errors of Metabolism (ICIEM)
  12. Today's Research Reports on Stocks to Watch: Amicus Therapeutics Inc. and Ritter Pharmaceuticals Inc.
  13. [$$] Clinical Development News, Aug. 14-18
  14. Amicus Therapeutics Announces Approval for Galafold™ (Migalastat) for Treatment of Fabry Disease in Australia
  15. Edited Transcript of FOLD earnings conference call or presentation 7-Aug-17 12:30pm GMT
  16. The Sole Reason Amicus Therapeutics, Inc. Exploded 29% Higher in July
  17. Amicus Therapeutics reports 2Q loss
  18. Amicus Therapeutics Announces Second Quarter 2017 Financial Results and Corporate Updates
  19. Investor Network: Amicus Therapeutics, Inc. to Host Earnings Call
  20. Amicus Therapeutics to Announce Second Quarter 2017 Financial Results on August 7, 2017

SEC Filings

  1. 8-K - Current report 171091093
  2. 8-K - Current report 171082197
  3. 8-K - Current report 171071668
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 171010626
  5. 8-K - Current report 171009982
  6. 8-K - Current report 17963889
  7. 424B5 - Prospectus [Rule 424(b)(5)] 17963789
  8. 424B5 - Prospectus [Rule 424(b)(5)] 17962228
  9. 8-K - Current report 17959108
  10. 8-K - Current report 17933726